Pliant Therapeutics (PLRX) Current Assets (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Current Assets of $174.9 million for Q1 2026, down 43.79% year-over-year from $311.2 million in Q1 2025, and down 10.95% quarter-over-quarter from $196.4 million in Q4 2025.
Pliant Therapeutics (PLRX) Current Assets (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Current Assets for 8 consecutive years, with $174.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 43.79% year-over-year to $174.9 million; the TTM figure through Mar 2026 stood at $174.9 million (down 43.79% YoY), while the FY2025 annual figure was $196.4 million, down 45.77% from the prior year.
- Current Assets fell to $174.9 million in Q1 2026 per PLRX's latest filing, from $196.4 million in the prior quarter.
- Across five years, Current Assets topped out at $588.2 million in Q1 2023 and bottomed at $173.5 million in Q2 2022.
- Historically, Current Assets has averaged $362.6 million across 5 years, with a median of $362.3 million in 2024.
- Annual changes were most pronounced in 2023 — Current Assets soared 226.0% — and 2025, when it sank 45.77%.
- Pliant Therapeutics' Current Assets stood at $340.3 million in 2022, then surged by 48.54% to $505.5 million in 2023, then dropped by 28.34% to $362.3 million in 2024, then tumbled by 45.77% to $196.4 million in 2025, then declined by 10.95% to $174.9 million in 2026.
- Business Quant data shows PLRX's Current Assets at $174.9 million in Q1 2026, $196.4 million in Q4 2025, and $245.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Pliant Therapeutics | 70.59 Mn | 70.59 Mn | - | 163.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 163.14 Mn |
| Mar 31, 2026 | 174.93 Mn |
| Dec 31, 2025 | 196.45 Mn |
| Sep 30, 2025 | 245.59 Mn |
| Jun 30, 2025 | 267.44 Mn |
| Mar 31, 2025 | 311.19 Mn |
| Dec 31, 2024 | 362.26 Mn |
| Sep 30, 2024 | 410.03 Mn |
| Jun 30, 2024 | 447.55 Mn |
| Mar 31, 2024 | 489.90 Mn |
| Dec 31, 2023 | 505.50 Mn |
| Sep 30, 2023 | 534.34 Mn |
| Jun 30, 2023 | 565.70 Mn |
| Mar 31, 2023 | 588.23 Mn |
| Dec 31, 2022 | 340.31 Mn |
| Sep 30, 2022 | 365.97 Mn |
| Jun 30, 2022 | 173.53 Mn |
| Mar 31, 2022 | 185.36 Mn |
| Dec 31, 2021 | 209.44 Mn |
| Sep 30, 2021 | 228.58 Mn |